Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and pharmacokinetic study of radiolabeled LOU064 in healthy volunteers
NL-OMON49324Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of remibrutinib in autoimmune disease and chronic inflammatory conditions (3 arms), sponsored by Novartis. Primary endpoints: Rates and routes of excretion, Pharmacokinetics of total radioactivity and 1 more. Started Aug 2019; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
autoimmune diseasechronic inflammatory conditions
Beyond the preview
Go deeper on NL-OMON49324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49324.